Etodesnitazene is classified as a novel opioid of the benzimidazole sub-class and is structurally dissimilar from fentanyl.
Novel opioids have been reported to cause psychoactive effects similar to heroin, fentanyl, and other opioids. Novel opioids have also caused adverse events, including death, as described in the literature.
Data suggest that this group of nitrocontaining analogues can have potency similar to or greater than fentanyl.
Recent in vitro data suggest that etodesnitazene is less potent than fentanyl. Etodesnitazene is not explicitly scheduled in the United States; however, etonitazene and isotonitazene are Schedule I substances.
According to an NPS Alert Etodesnitazene has been identified in one case since December 2020 (1/23/21) in Oregon.
December 7, 2021 – The Drug Enforcement Administration issued a notice of intent to publish a temporary order to schedule seven synthetic benzimidazole-opioid substances. Read the full announcement here.